Why the study?
The extent of subclinical aortic atherosclerosis measured by 3D CMR and its interrelations with CT calcium scores and carotid intima-media thickness in asymptomatic familial versus nonfamilial hypercholesterolemia required comparison.
Does the presence of a pathogenic familial hypercholesterolemia gene mutation increase subclinical aortic, coronary, and carotid atherosclerosis burden compared with severe nonfamilial hypercholesterolemia in asymptomatic adults?
Cross-Sectional (n=90)
No
Does the presence of a pathogenic familial hypercholesterolemia gene mutation increase subclinical aortic, coronary, and carotid atherosclerosis burden compared with severe nonfamilial hypercholesterolemia in asymptomatic adults?
Answers are grounded in this paper and cite their sources.
Asymptomatic patients with monogenic heterozygous familial hypercholesterolemia have a significantly more pronounced and diffuse subclinical aortic atherosclerosis burden on 3D CMR than patients with severe nonfamilial hypercholesterolemia, independent of LDL-C levels.
We aimed to compare the extent of subclinical atherosclerosis in the ascending and descending aortas by measuring wall area and thickness using 3D cardiovascular magnetic resonance imaging (aAWAI and dAWAI) in patients with asymptomatic familial hypercholesterolemia (FH) and nonfamilial hypercholesterolemia (NFH). We also aimed to establish the interrelations of CMR parameters with other subclinical atherosclerosis measurements, such as calcium scores, obtained using computed tomography in coronary arteries (CCS) and ascending and descending aorta (TCSasc and TCSdsc), as well as the carotid intima-media thicknesses (cIMT) using ultrasonography. A total of 60 patients with FH (29 men and 31 women), with a mean age of 52.3 ± 9.6 years, were analyzed. A subclinical atherosclerosis assessment was also performed on a group consisting of 30 age- and gender-matched patients with NFH, with a mean age of 52.5 ± 7.9 years. We found the ascending and descending aortic wall areas and thicknesses in the FH group to be significantly increased than those of the NFH group. A multivariate logistic regression analysis showed that a positive FH mutation value was a strong predictor of high aAWAI and dAWAI independent of the LDL cholesterol level. Correlations across CMR atherosclerotic parameters, calcium scores, and cIMT in the FH and NFH groups, were significant but low. Most of the atherosclerosis tests with high results belonged to the FH group. We found that patients with documented heterozygous FH had a higher atherosclerosis burden in the aorta compared to patients with severe hypercholesterolemia without FH gene mutation. Atherosclerosis is not severe in asymptomatic patients with FH, but is more pronounced and also more diffuse than in patients with NFH. The etiology of hypercholesterolemia, and not just cholesterol levels, plays a significant role in determining the degree of subclinical atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Gałąska et al. (2023) conducted a cross-sectional in Asymptomatic familial hypercholesterolemia (FH) and nonfamilial hypercholesterolemia (NFH) (n=90). Familial hypercholesterolemia (FH) gene mutation vs. Nonfamilial hypercholesterolemia (NFH) without FH gene mutation was evaluated on High indexed ascending aortic wall area (aAWAI in top tercile) on 3D cardiovascular magnetic resonance imaging (OR 16.55, 95% CI 3.44-83.5, p=0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: